Medicare Enrolled
Dr. Vino Verghese, MD
Gastroenterology · Burlingame, CA
Practice pattern: Clinical Cardiology
— Primarily office-based clinical cardiology
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Verghese from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Verghese?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Verghese
Dr. Vino Verghese is a gastroenterology specialist in Burlingame, CA, with 20 years of NPI registration. Based on federal Medicare data, Dr. Verghese performed 1,050 Medicare services across 990 unique beneficiaries.
Between the years covered by Open Payments, Dr. Verghese received a total of $6,107 from 28 pharmaceutical and/or device companies across 170 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in gastroenterology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Verghese is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 20 years in practice
▲ Top 32% volume in CA
$6,107 industry payments
Medicare Practice Summary
Medicare Utilization ↗1,050
Medicare services
Top 32% in CA for gastroenterology
990
Unique beneficiaries
$143
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~52 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
245 | $110 | $364 |
| Colon polyp removal with endoscopic snare This procedure removes polyps or growths from the large bowel using a flexible tube with a camera and a wire loop tool. The snare is used to cut off the growths during the examination. |
129 | $230 | $2,403 |
| Upper GI endoscopy with biopsy A procedure to collect tissue samples from the esophagus, stomach, or upper small intestine using a flexible tube with a camera. The samples are examined to check for abnormalities. |
90 | $76 | $1,270 |
| Initial hospital admission, moderate complexity Initial hospital inpatient or observation care for a new patient involving moderate-level medical decision making, with at least 55 minutes total time on the date of the encounter. |
79 | $111 | $478 |
| Colonoscopy with biopsy A procedure to collect tissue samples from the large intestine using a flexible tube with a camera. The samples are examined to check for abnormalities or disease. |
58 | $140 | $1,927 |
| Upper endoscopy (EGD) A diagnostic exam of the esophagus, stomach, and upper small bowel using a flexible endoscope. |
57 | $86 | $1,170 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
51 | $69 | $252 |
| New patient office visit (30-44 min) An initial office visit for a new patient lasting between 30 and 44 minutes. This code is used when the total time spent on the date of the encounter falls within this range. |
49 | $95 | $365 |
| Colonoscopy for colorectal cancer screening, high risk A colonoscopy performed to screen for colorectal cancer in individuals identified as being at high risk for the disease. |
46 | $205 | $1,514 |
| Endoscopic incision of pancreatic outlet A procedure where a flexible endoscope is used to make an incision in the pancreatic outlet. |
37 | $47 | $966 |
| Endoscopic removal of bile or pancreatic duct stone A flexible endoscope is used to remove stones or debris from the bile or pancreatic ducts. |
36 | $238 | $1,824 |
| Endoscopic ultrasound-guided needle biopsy A procedure using an ultrasound-equipped endoscope to guide a needle for tissue sampling of the esophagus, stomach, or upper small bowel. |
35 | $207 | $1,588 |
| Colonoscopy for colorectal cancer screening A colonoscopy performed to screen for colorectal cancer in individuals who are not at high risk for the disease. |
29 | $204 | $1,495 |
| Endoscopic ultrasound of esophagus, stomach, or upper small bowel An ultrasound exam of the esophagus, stomach, and/or upper small bowel performed using a flexible endoscope. |
28 | $189 | $1,185 |
| Colonoscopy A diagnostic exam of the large bowel using a flexible endoscope to visualize the interior of the colon. |
28 | $150 | $1,497 |
| Pancreatic or bile duct stent insertion A flexible endoscope is used to place a stent into the pancreatic or bile duct to keep it open. |
20 | $404 | $1,878 |
| Stent replacement in pancreatic or bile duct A flexible endoscope is used to remove an existing stent and insert a new one into the pancreatic or bile duct. |
11 | $406 | $1,884 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
11 | $129 | $554 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
11 | $71 | $247 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
3.0% high complexity
35.3% medium
61.7% routine
Industry Payment Transparency
Open Payments through 2024 ↗$6,107
Total received (2018-2024)
Avg $872/year across 7 years
Top 26% in CA for gastroenterology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
28
Companies
170
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$6,107 (100.0%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$800
2023
$1,667
2022
$2,166
2021
$367
2020
$443
2019
$279
2018
$385
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
ABBVIE INC.
$257
PFIZER INC.
$131
Janssen Biotech, Inc.
$128
Lilly USA, LLC
$97
Fresenius Kabi USA, LLC
$32
Ipsen Biopharmaceuticals, Inc
$28
Celltrion USA Inc.
$28
Salix Pharmaceuticals, a division of Bausch Health US, LLC
$25
Takeda Pharmaceuticals U.S.A., Inc.
$20
QOL Medical, LLC
$20
Braintree Laboratories, Inc.
$17
AIMMUNE THERAPEUTICS, INC.
$17
Top 3 companies account for 64.5% of 2024 payments
All-time payments by company (2018-2024) ›
Boston Scientific Corporation
$1,767
AbbVie Inc.
$790
Olympus Corporation of the Americas
$711
ABBVIE INC.
$631
Janssen Biotech, Inc.
$375
Takeda Pharmaceuticals U.S.A., Inc.
$374
Apollo Endosurgery US Inc
$342
PFIZER INC.
$214
QOL Medical, LLC
$139
Lilly USA, LLC
$97
INTERCEPT PHARMACEUTICALS, INC.
$73
Salix Pharmaceuticals, a division of Bausch Health US, LLC
$70
AbbVie, Inc.
$67
Merck Sharp & Dohme LLC
$63
Ferring Pharmaceuticals Inc.
$51
Gilead Sciences, Inc.
$48
NESTLE HEALTHCARE NUTRITION INC.
$43
Nestle HealthCare Nutrition Inc.
$36
Braintree Laboratories, Inc.
$34
Fresenius Kabi USA, LLC
$32
Ipsen Biopharmaceuticals, Inc
$28
Celltrion USA Inc.
$28
Alfasigma USA, Inc.
$20
Intercept Pharmaceuticals, Inc.
$17
AIMMUNE THERAPEUTICS, INC.
$17
Merck Sharp & Dohme Corporation
$15
Medtronic, Inc.
$15
Allergan Inc.
$13
Top 3 companies account for 53.5% of all-time payments
Associated products mentioned in payments ›
Bylvay · CLENPIQ · CREON · DIFICID · DISPOSABLE DISTAL ATTACHMENT · ENTYVIO · Entyvio · GENERAL BILIARY DEVICES · GI GENIUS · HUMIRA · Humira · IDACIO · LINZESS · MAVYRET · MOTEGRITY · Mavyret · OCALIVA · OMVOH · ORISE · Orbera · REBYOTA · REMICADE · RINVOQ · Resolution Clip · SKYRIZI · SPYGLASS · STELARA · SUCRAID · SUFLAVE · SUTAB · Single Use Electrosurgical Knife KD-655 · Sucraid · TREMFYA · TRULANCE · VEGZELMA · VIBERZI · XELJANZ · XIFAXAN · ZENPEP
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (100%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Geographic Context
Gastroenterologists within 10 mi
226
Per 100K population
30.3
County median income
$156,000
Nearest hospital
PENINSULA MEDICAL CENTER
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Verghese is a clinical cardiology specialist, with moderate Medicare volume, with low-engagement industry engagement, with 20 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Verghese experienced with office visit, established patient (30-39 min)?
Based on Medicare claims data, Dr. Verghese performed 245 office visit, established patient (30-39 min) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Verghese receive payments from pharmaceutical companies?
Yes. Dr. Verghese received a total of $6,107 from 28 companies across 170 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Verghese's costs compare to other gastroenterologists in Burlingame?
Dr. Verghese's average Medicare payment per service is $143. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Verghese) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Specialty guide
Understanding Gastroenterology
Common procedures, typical costs, and what industry payments mean in gastroenterology.
Same specialty & city
Gastroenterologists in Burlingame
Browse gastroenterologists in Burlingame ranked by procedure volume and transparency data.
Highest volume
Top Gastroenterologists in CA
Gastroenterologists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Gastroenterologists in CA
Which CA gastroenterologists receive the most from drug and device companies.
By company
Boston Scientific Corporation Payments to Doctors
See all physicians who received payments from Boston Scientific Corporation.
By company
AbbVie Inc. Payments to Doctors
See all physicians who received payments from AbbVie Inc.
By company
Olympus Corporation of the Americas Payments to Doctors
See all physicians who received payments from Olympus Corporation of the Americas.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology